The American Society for Aesthetic Plastic Surgery (ASAPS), is hosting a panel discussion today on the fast-evolving practice of fat grafting, and how surgeons are discovering best practices to produce the most natural looking results. Physician members of ASAPS concur that less is more when it comes to utilizing a patient’s own fat to enhance certain anatomical regions including the breast and buttocks. Further, they agree that fat grafting is proving to be a novel technique for body sculpting previously neglected areas including women’s and men’s shoulders, pectorals, legs and stomachs to create definition.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310752-asaps-plastic-surgery-fat-grafting/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
In an effort to support the health and wellness of its guests nationwide, Dickey’s Barbecue Pit has announced that all meats sold in every location will contain “No B.S.” (Bad Stuff) by sourcing only responsibly raised, quality meats. Starting August 15, all chicken sold will now be raised without antibiotics. This breakthrough in sustainability not only comprises the brand’s traditional slow smoked chicken breast, but also will include whole smoked chickens and chicken nuggets served in kids’ meals at select stores. To learn more, click here.
The chicken is 100% vegetarian fed and humanely raised. It is also completely hormone-free and cage-free, ensuring that Dickey’s guests are served only the highest quality poultry with no additives. This announcement accompanies other advances in sustainability by the barbecue brand including humanely handled and sustainably raised brisket as well as locally-made sausage with no nitrates, nitrites* or artificial coloring or flavors. Additionally, all of Dickey’s pork products are free from added hormones**, nitrates, nitrites* and artificial coloring and flavors.
To view the multimedia release go to:
http://www.multivu.com/players/English/7717951-dickeys-barbecue-pit-no-bad-stuff-initiative/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Producido para NVidia, Oreck, Energizer y Lee --
Las grandes empresas están ayudando a encontrar una cura a través de donaciones, la venta de productos de color rosado y la creación de una technologia revolucionaria de escaneo del mama . Aquí están algunas maneras que usted puede ayudar.
Board certified plastic surgeon in Los Angeles Dr. Geoffrey Keyes on Good Morning America discusses the candidates for plastic surgery. http://www.keycare.com or http://www.lookingyourbest.com
Medela today announced the U.S. launch of Calma, a product designed exclusively for breastfed babies to support mothers in their breastfeeding journey. Calma is a research-based nipple used with a BPA-free breastmilk bottle designed to help babies to maintain their natural feeding behavior and transition from bottle back to breast with ease — a revolution for breastfeeding mothers.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53588-medela-announces-u-s-launch-of-calma-for-breastfeeding
Simona Halep from Romania is planning a surgical breast reduction in order to improve her performance. Do the fans agree that this is a good idea? Find out on Fanarchy, Tuesdays at 10:30ET on VERSUS.
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
